Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146,601 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
Shi Y, Chen J, Zhang H, Zhang Z, Zhang Y, Wang Z, Zhang S, Zhao J, Liu C, Wang X, Zhao Y, Hu C, Yang L, Hao X, Wang L, Liu Y, Yu Y, Zhao J, Wang M, Zhang L, Sun S, Hu Y, Gu K, Hang X, Shan J, Zhang Y, Tan B, Yang W, Yang R, Si M, Geng H, Li H, Kang X. Shi Y, et al. Among authors: wang x, wang l, wang z, wang m. BMC Med. 2023 Feb 24;21(1):72. doi: 10.1186/s12916-023-02738-5. BMC Med. 2023. PMID: 36829154 Free PMC article. Clinical Trial.
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C, Liu Z, Guo H, Yu G, Ji Z, Ying J, Ling Y, Yu S, Hu Y, Guo J, Fang J, Zhou A, Guo J. Sheng X, et al. Among authors: wang l. J Clin Oncol. 2024 Apr 20;42(12):1391-1402. doi: 10.1200/JCO.22.02912. Epub 2023 Nov 21. J Clin Oncol. 2024. PMID: 37988648 Free PMC article. Clinical Trial.
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing.
Xu Z, Li Y, Wang L, Hao X, Ying J, Li J, Xing P. Xu Z, et al. Among authors: wang l. Expert Rev Anticancer Ther. 2024 Mar-Apr;24(3-4):183-192. doi: 10.1080/14737140.2024.2334807. Epub 2024 Apr 17. Expert Rev Anticancer Ther. 2024. PMID: 38526910
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.
Chen X, Wang W, Zou Q, Zhu X, Lin Q, Jiang Y, Sun Y, Shen L, Wang L, Zou G, Lin X, Lin S, Li M, Wang Y, Xu R, Ao R, Wang R, Lin H, Huang S, Xu T, Li W, Xia M, Xia Y, Wang Z, Li B, Li J, Hu C. Chen X, et al. Among authors: wang w, wang l, wang z, wang y, wang r. Signal Transduct Target Ther. 2024 Jun 19;9(1):148. doi: 10.1038/s41392-024-01865-6. Signal Transduct Target Ther. 2024. PMID: 38890298 Free PMC article. Clinical Trial.
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.
Lei H, Ling Y, Yuan P, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Han W, Hu C, Chi Z, Cui C, Si L, Fang J, Guo J, Sheng X, Zhou A, Ying J. Lei H, et al. Among authors: wang l. J Natl Cancer Cent. 2023 Mar 1;3(2):121-128. doi: 10.1016/j.jncc.2023.02.003. eCollection 2023 Jun. J Natl Cancer Cent. 2023. PMID: 39035731 Free PMC article.
Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in China.
Wang S, Liu J, Wang Y, Hu Y, Liu Z, Yao Y, Liang L, Liu Y, Wang L, Li J, Xing P. Wang S, et al. Among authors: wang l, wang y. Chin J Cancer Res. 2024 Aug 30;36(4):398-409. doi: 10.21147/j.issn.1000-9604.2024.04.04. Chin J Cancer Res. 2024. PMID: 39246703 Free PMC article.
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
Zhang S, Wang W, Xu C, Zhang Y, Cai X, Wang Q, Song Z, Li Z, Yu J, Zhong W, Wang Z, Liu J, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Lin G, Huang L, Yuan J, Jiang Z, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Zhou J, Zhu Z, Pan W, Dong X, Pang F, Wang K, Yao C, Lin G, Li S, Yang Z, Luo J, Jia H, Nie X, Wang L, Zhu Y, Hu X, Xie Y, Lin X, Cai J, Xia Y, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Kang J, Zhang J, Zhang C, Gao W, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Wan B, Lv D, Yu G, Shi L, Xia Y, Gao F, Zhang X, Xu T, Zhou W, Wang H, Liu Z, Yang N, Wu L, Wang Q, Wang G, Hong Z, Wang J, Fang M, Fang Y, Zhang Y, Song Y, Ma S, Fang W, Lu Y. Zhang S, et al. Among authors: wang h, wang w, wang g, wang l, wang k, wang z, wang j, wang d, wang q. Thorac Cancer. 2023 Jan;14(1):91-104. doi: 10.1111/1759-7714.14743. Epub 2022 Nov 28. Thorac Cancer. 2023. PMID: 36444143 Free PMC article.
146,601 results
You have reached the last available page of results. Please see the User Guide for more information.